Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity.
about
Mesenchymal stem cells as a vector for the inflammatory prostate microenvironmentTyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functionsReceptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancersCombined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancerDocetaxel-loaded lipid microbubbles combined with ultrasound-triggered microbubble destruction for targeted tumor therapy in MHCC-H cellsProstate cancer and bone: the elective affinities.The inflammatory chemokine CCL5 and cancer progressionThe role of CCL5 in the ability of adipose tissue-derived mesenchymal stem cells to support repair of ischemic regionsThe osteoblastic and osteoclastic interactions in spinal metastases secondary to prostate cancer.Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition.Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells.Epidermal growth factor receptor is associated with the onset of skeletal related events in non-small cell lung cancer.How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive.Clinical-grade quality platelet-rich plasma releasate (PRP-R/SRGF) from CaCl2 -activated platelet concentrates promoted expansion of mesenchymal stromal cells.Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer.
P2860
Q26853374-7223C1F5-42C5-40B4-8B7E-95E3F3461F57Q28078946-6773FA4B-3166-434B-B719-473D9A014F91Q28082793-5A934982-3DF0-420F-9A49-2099F2CC38ADQ28534382-EB234113-FF0A-4F75-9D28-611EA7DDF6EEQ30376445-7FECF03C-44AF-4142-99B2-43585C20C650Q33757791-0898A2AA-3A39-4BE1-8FE7-395C4B36A065Q37541911-C44ECAE2-0B31-49BD-8A0E-303FC9304ADEQ37592479-F6F93C43-9463-4A6D-93CB-46FB2937F4DDQ37615017-5E163FEB-D9BB-4B00-A604-530360B5A5CDQ38696082-5BC652A0-21C3-441F-821A-DAF345DC140BQ42335714-25816B9C-092A-4F0B-98F3-5C7E41BD4B14Q43555541-73868289-F2E3-45B9-AFC5-05F1F62003B3Q52668325-DF174C74-5B6E-43B0-91F5-DFD30675416CQ53122359-D5C5508A-B1F4-4F4C-9D8B-A55CA9373854Q55021572-B1564231-858F-4586-B084-5743F4AE74A9
P2860
Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Gefitinib inhibits the cross-t ...... ibition of docetaxel activity.
@en
Gefitinib inhibits the cross-t ...... ibition of docetaxel activity.
@nl
type
label
Gefitinib inhibits the cross-t ...... ibition of docetaxel activity.
@en
Gefitinib inhibits the cross-t ...... ibition of docetaxel activity.
@nl
prefLabel
Gefitinib inhibits the cross-t ...... ibition of docetaxel activity.
@en
Gefitinib inhibits the cross-t ...... ibition of docetaxel activity.
@nl
P2093
P2860
P50
P356
P1476
Gefitinib inhibits the cross-t ...... hibition of docetaxel activity
@en
P2093
Cinzia Borghese
Lara Cattaruzza
Marta Celegato
P2860
P304
P356
10.1002/JCB.24456
P577
2013-05-01T00:00:00Z